Reimbursement
How medical device reimbursement works: coding, coverage and payment
Medical device reimbursement explained: how coding, Medicare coverage and payment systems fit together, and what a medtech reimbursement strategy has to cover.
By the All In MedTech editorial team · Published November 19, 2026 · 6 min read
Medical device reimbursement is how the hospital, clinic or physician who uses a device gets paid for it. It rests on three separate questions: coding (is there a code that describes the procedure or product), coverage (will the payer pay for it at all, and for which patients) and payment (how much). A device needs a workable answer to all three before it can be used routinely.
FDA authorization is a separate step. FDA decides whether a device is safe and effective enough to market. Payers decide whether to pay for it. This guide explains each piece, using Medicare as the main example because it is the largest single payer for many device categories and its rules are public.
Why FDA clearance is not the same as payment
A 510(k) clearance, De Novo grant or PMA approval lets a company sell a device in the US. It says nothing about who will pay. Medicare's test is different: under section 1862(a)(1)(A) of the Social Security Act, Medicare does not pay for items and services that are not "reasonable and necessary for the diagnosis or treatment of illness or injury." That is a judgment about benefit to Medicare patients, and it can require evidence beyond what FDA needed.
The gap matters most for novel devices. A device cleared on bench testing through a 510(k) may still need clinical outcome data to persuade payers. For background on the FDA side, see 510(k) vs De Novo vs PMA.
Coding: describing what was done
Codes are the language of claims. Several code sets are involved, and they do different jobs.
| Code set | What it describes | Who maintains it | Main setting |
|---|---|---|---|
| CPT (HCPCS Level I) | Procedures and services by physicians and other practitioners | American Medical Association | Physician and outpatient claims |
| HCPCS Level II | Products, supplies and some services not in CPT, including many devices, durable equipment and drugs | CMS | Outpatient, supplier and durable equipment claims |
| ICD-10-CM | Diagnoses | CDC's National Center for Health Statistics | All settings |
| ICD-10-PCS | Inpatient procedures | CMS | Hospital inpatient claims |
| MS-DRG | Groups of inpatient stays with similar cost, assigned from the diagnosis and procedure codes | CMS | Hospital inpatient payment |
A few points help in practice.
- CPT codes describe the clinician's work, not the device. A new device can often be used under an existing CPT code if the procedure is the same. If not, the AMA's CPT Editorial Panel decides on new codes, including temporary codes for emerging technology. CPT descriptors are copyrighted by the AMA.
- HCPCS Level II codes can describe the device itself. CMS reviews applications for non-drug items on a biannual cycle through its online system, MEARIS. CMS's HCPCS Level II coding procedures page lists the current deadlines.
- ICD-10-PCS codes for new inpatient procedures are requested through the ICD-10 Coordination and Maintenance Committee, which meets twice a year.
Having a code does not guarantee coverage or adequate payment. It simply makes the service visible on a claim.
Coverage: will Medicare pay at all
Medicare coverage for a device is decided in one of three ways.
- National Coverage Determination (NCD). CMS decides for the whole country. NCDs bind every Medicare contractor. Some NCDs cover a service only within approved studies, an approach called coverage with evidence development.
- Local Coverage Determination (LCD). Where there is no NCD, a Medicare Administrative Contractor (MAC) can write a policy for its region. CMS lists 12 A/B MACs and 4 durable equipment MACs.
- Claim by claim. Many services have no written policy. The MAC decides individual claims under the reasonable and necessary standard.
The difference between NCDs and LCDs, and how each is developed, is covered in Medicare NCDs vs LCDs. For certain Breakthrough devices, CMS also offers the TCET pathway, which aims to speed national coverage.
Medicare can also cover devices used in some clinical trials. Under 42 CFR 405.201 to 405.215, Medicare may cover devices in FDA-approved Category B investigational device exemption studies, and routine care in Category A studies, when CMS criteria are met. See how device clinical trials work.
Payment: how much the provider receives
Medicare pays through different systems depending on where care happens. In most of them the device is not paid separately. Its cost is folded into the payment for the procedure or stay.
- Hospital inpatient (IPPS). Each stay is assigned an MS-DRG, and the hospital receives a set amount for that DRG, adjusted for local wages and other factors. The device cost is inside that amount. CMS recalibrates DRG weights each year from hospital claims and cost data.
- Hospital outpatient (OPPS). Services are grouped into Ambulatory Payment Classifications (APCs). Many device-intensive procedures are paid through comprehensive APCs that bundle related items.
- Ambulatory surgical centers. Payment is generally tied to the OPPS rates.
- Physician Fee Schedule. Pays clinicians using relative value units for work, practice expense and malpractice. Supplies used in the office can be part of the practice expense.
- Durable medical equipment (DMEPOS). Items such as some home-use devices are paid under a fee schedule, with competitive bidding for some categories.
Payment rates change every year through rulemaking. CMS publishes proposed and final rules for each system, usually in the spring and summer for inpatient care and in the summer and fall for outpatient and physician payment. Check the current rule rather than relying on any figure you see quoted.
Add-on and transitional payments for new technology
Because bundled payments are based on past cost data, a new and more expensive device can be underpaid for its first years. Medicare has two main temporary fixes.
- New Technology Add-on Payment (NTAP) in the inpatient system pays part of the cost of a qualifying new technology on top of the DRG payment. See NTAP explained.
- Transitional pass-through payment in the outpatient system pays separately for a qualifying new device category for two to three years. See device pass-through explained.
The outpatient system also has New Technology APCs, which can assign a payment rate to a new procedure that has no cost history yet.
Each program has eligibility criteria, application deadlines and limited duration. Both NTAP and pass-through have an alternative pathway for FDA Breakthrough devices, which is one reason companies seek Breakthrough designation.
Beyond Medicare
Commercial insurers and Medicare Advantage plans make their own decisions, though many reference Medicare policy. Medicare Advantage plans must generally cover what traditional Medicare covers, including NCDs and applicable LCDs, but they can apply their own utilization management such as prior authorization. Commercial payers publish medical policies and often look for peer-reviewed outcome data, guideline support and evidence of cost impact.
Hospitals add another layer. Value analysis committees review new devices for clinical benefit and cost before a hospital will buy them, and they look closely at whether payment covers the device.
What a reimbursement strategy covers
A reimbursement plan for a new device usually works through these questions, ideally well before FDA submission:
- Site of care. Inpatient, outpatient, office or home, since each has its own payment system.
- Existing codes. Whether current CPT, HCPCS Level II and ICD-10-PCS codes describe the procedure and device, or new ones are needed.
- Coverage status. Whether an NCD or LCDs already apply, and what evidence they require.
- Payment adequacy. Whether the current DRG or APC payment covers the device cost, and whether NTAP, pass-through or a New Technology APC could apply.
- Evidence plan. Whether the pivotal study will produce the outcomes payers want, such as fewer complications, readmissions or repeat procedures, not only what FDA requires.
- Timeline. Coding, coverage and payment cycles each run on fixed annual or semi-annual calendars, and missing a deadline can mean a year's delay.
Public data helps with the early steps. You can see which coverage documents mention a technology, which Breakthrough devices are in a field, and what clinical trials competitors are running. This site does not give coding or billing advice for specific cases, and CMS, the MACs and the AMA are the authoritative sources.
For the official starting points, see CMS's Medicare Coverage Database and its pages on the inpatient and outpatient payment systems.
Frequently asked questions
- What are the three parts of medical device reimbursement?
- Coding describes what was done or supplied, coverage decides whether the payer will pay for it at all, and payment sets how much the provider receives.
- Does FDA clearance mean Medicare will pay for a device?
- No. FDA decides whether a device can be marketed, while Medicare separately decides whether the device is reasonable and necessary for its beneficiaries and how it is paid.
- Who decides Medicare coverage for a new device?
- CMS can set national coverage through a National Coverage Determination, and where there is none, the regional Medicare Administrative Contractor decides through Local Coverage Determinations or claim by claim.
- Is a device usually paid for separately?
- Usually not. In hospitals the device cost is normally bundled into the payment for the procedure, which is why add-on and pass-through payments exist for new, costly technology.
For information only, not medical, legal or investment advice. Facts about FDA, CMS and SEC rules are current as of the publication date; check the linked official source for changes.